← Back to Clinical Trials
Recruiting NCT05180253

NCT05180253 Esophageal and Gastric Registry and Biorepository

◆ AI Clinical Summary
Plain-language summary for patients
Clinical Trial Summary
NCT ID NCT05180253
Status Recruiting
Phase
Sponsor University of Louisville
Condition Gastro Esophageal Reflux
Study Type OBSERVATIONAL
Enrollment 40 participants
Start Date 2023-01-09
Primary Completion 2026-06

Eligibility & Interventions

Sex All sexes
Min Age 18 Years
Max Age 85 Years
Study Type OBSERVATIONAL
Interventions
Esophageal studies

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 40 participants in total. It began in 2023-01-09 with a primary completion date of 2026-06.

⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.

Brief Summary

The evaluation of the foregut, the esophagus and stomach, has come a long way over the past two decades, and continues to experience exciting discoveries in the clinical evaluation of foregut physiology. Assessing esophageal peristalsis has relied for the past several decades on High Resolution Manometry (HRM), however it has recently become known that even though HRM is an extremely effective tool, that there are certain subsets of patients in which additional information is required. Additionally, the assessment of esophageal reflux disease has relied on pH impedance for the last two decades. However, this procedure requires a catheter to be passed through a nostril and remain in place for at least 24 hours. Novel techniques, already FDA approved, including EndoFLIP for esophageal peristalsis and mucosal integrity (MI) for reflux disease, have emerged as time-of-endoscopy assessments. Both involve the placement of a balloon through the scope at time of upper endoscopy (standard first line assessment for both dysphagia and reflux symptoms) and are quick and pose little-to-no additional risk or discomfort for patients. However, data regarding normal esophageal parameters are poorly defined for both EndoFLIP and MI. Additionally, EndoFLIP has increasingly been used to assess the pylorus, and scarce data exists there regarding how a tool originally envisioned for esophageal assessment can be used more distally in the GI tract. We will recruit healthy, asymptomatic volunteers to undergo testing with MI and FLIP (esophageal and pyloric). The data obtained will help establish the benchmark from which assessments can be made in patients.

Eligibility Criteria

Inclusion Criteria: * Age 18-85 * No prior surgical history * Asymptomatic according to gastroesophageal and gastric questionnaires * Not currently taking any medications that affect acid secretion or gut motility * No history of malignancy * No mental health issues precluding informed consent * No smoking history * No excessive or daily alcohol use * BMI \< 30 * No known hiatus hernia * No known medical illness (autoimmune, neurological) that could be associated with altered esophageal or gastric function * Not allergic to fentanyl or versed * No history of eating disorder * No history of autoimmune disorders Exclusion Criteria: * Minors * Surgeries involving the GI tract * Medication use affecting acid secretion or gut motility * Personal history of malignancy * Mental health issues precluding informed consent * Symptoms on standard clinical questionnaires * Pregnant - the effect that pregnancy has on esophageal and gastric motility is not well defined, but we will need to eliminate this as a confounding factor * Nursing women - although the investigations are FDA approved and part of standard clinic practices, they are time consuming and involve medication administration that might affect the ability of a mother to nurse

Frequently Asked Questions

Who can join the NCT05180253 clinical trial?

This trial is open to participants of all sexes, aged 18 Years or older, up to 85 Years, studying Gastro Esophageal Reflux. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.

Is NCT05180253 currently recruiting?

Yes, NCT05180253 is actively recruiting participants. Visit ClinicalTrials.gov or contact University of Louisville to inquire about joining.

Where is the NCT05180253 trial being conducted?

This trial is being conducted at Louisville, United States.

Who is sponsoring the NCT05180253 clinical trial?

NCT05180253 is sponsored by University of Louisville. The trial plans to enroll 40 participants.

Related Trials

ClinicalMetric — Independent clinical trial intelligence platform. Not affiliated with NIH, ClinicalTrials.gov, the U.S. FDA, or any pharmaceutical company, hospital, or clinical research organization. Trial data is sourced from ClinicalTrials.gov for informational purposes only and does not constitute medical advice. Do not make any treatment, enrollment, or health decisions based solely on information found here — always consult a qualified healthcare professional. Full Disclaimer  ·  Last Reviewed: April 2026  ·  Data Methodology